| Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study SJ Wang, AA Roxas Jr, B Saravia, BK Kim, D Chowdhury, N Riachi, ... Cephalalgia 41 (13), 1285-1297, 2021 | 51 | 2021 |
| Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful … ASC Rice, RH Dworkin, NB Finnerup, N Attal, P Anand, R Freeman, ... Pain 162 (10), 2578-2589, 2021 | 46 | 2021 |
| Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study MD Ferrari, U Reuter, PJ Goadsby, GP da Silva Lima, S Mondal, S Wen, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (3), 254-262, 2022 | 22 | 2022 |
| Efficacy and Safety of Erenumab in Patients with Episodic Migraine from the EMPOWER Study SJ Wang, A Roxas Jr, B Saravia, BK Kim, D Chowdhury, N Riachi, ... 18th Migraine Trust Virtual Symposium, 2020 | 8 | 2020 |
| Efficacy and safety of erenumab in participants with episodic migraine in whom 2–4 prior preventive treatments had failed: LIBERTY 3-year study U Reuter, PJ Goadsby, MD Ferrari, GP Da Silva Lima, S Mondal, J Kalim, ... Neurology 102 (10), e209349, 2024 | 5 | 2024 |
| Three-Year Efficacy and Safety of Erenumab in Participants with Episodic Migraine and 2–4 Prior Preventive Treatment Failures: Results from the LIBERTY Study (P1-1. Virtual) U Reuter, P Goadsby, M Ferrari, GP da Silva Lima, S Mondal, S Wen, ... Neurology 98 (18_supplement), 1100, 2022 | 1 | 2022 |
| Three-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study U Reuter, PJ Goadsby, D Ferrari, G Lima, P Da Silva, S Mondal, S Wen, ... Cephalalgia 41 (1S), 268, 2021 | 1 | 2021 |
| Effect of Erenumab on Patient-Reported Outcomes in Patients With Episodic Migraine From Asia, the Middle East and Latin America: The EMPOwER Study (P16-2.006) SJ Wang, AA Roxas Jr, B Saravia, B Kim, D Chowdhury, N Riachi, ... Neurology 98 (18_supplement), 1543, 2022 | | 2022 |
| Efficacy and Safety of Erenumab in Patients with Episodic Migraine in East Asia: Taiwan and Korea subpopulation analysis of the EMPOwER study SJ Wang, BK Kim, GPDS Lima, S Pandhi, S Wen, S Mondal, ... JOURNAL OF HEADACHE AND PAIN 22 (SUPPL 1), 115-116, 2021 | | 2021 |